No headlines found.
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
ACCESS Newswire (Tue, 3-Feb 4:05 PM ET)
ACCESS Newswire (Tue, 27-Jan 4:05 PM ET)
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
ACCESS Newswire (Tue, 20-Jan 4:05 PM ET)
ACCESS Newswire (Tue, 20-Jan 9:00 AM ET)
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
ACCESS Newswire (Thu, 18-Dec 9:00 AM ET)
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Aytu Biopharma trades on the NASDAQ stock market under the symbol AYTU.
As of February 27, 2026, AYTU stock price climbed to $2.55 with 50,323 million shares trading.
AYTU has a beta of 2.34, meaning it tends to be more sensitive to market movements. AYTU has a correlation of 0.23 to the broad based SPY ETF.
AYTU has a market cap of $27.37 million. This is considered a Sub-Micro Cap stock.
Last quarter Aytu Biopharma reported $15 million in Revenue and -$1.05 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.65.
In the last 3 years, AYTU traded as high as $3.50 and as low as $.95.
The top ETF exchange traded funds that AYTU belongs to (by Net Assets): VTI, VXF, DFSU, DFAS, DFAC.
AYTU has outperformed the market in the last year with a price return of +99.2% while the SPY ETF gained +16.4%. AYTU has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.4% and +17.0%, respectively, while the SPY returned +1.0% and +0.5%, respectively.
AYTU support price is $2.37 and resistance is $2.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AYTU shares will trade within this expected range on the day.